Recursion Pharmaceuticals
Publicly traded techbio company (NASDAQ: RXRX) industrialising drug discovery with AI and its own supercomputer.
Overview
Recursion is a Salt Lake City clinical-stage 'techbio' company decoding biology to industrialise drug discovery. Its Recursion OS platform pairs one of the largest proprietary biological and chemical datasets with machine learning to map cellular biology at scale. It runs BioHive-2, an NVIDIA DGX SuperPOD with 504 H100 GPUs — the fastest supercomputer owned by any pharma company — and received a $50M investment from NVIDIA. Recursion works through pharma partnerships and its own clinical pipeline.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 24 Jul 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
ASEAN Perspective
Recursion Pharmaceuticals in Southeast Asia
ASEAN-region availability and pricing notes coming soon. Drop the editorial team a note via /contact/ if you can supply local context (Singapore/Malaysia/Indonesia/Thailand/Vietnam).
What this is for: AI-driven, industrial-scale drug discovery combining large biological datasets, automated experiments and its own supercomputing.
Who this is for: Pharmaceutical and biotech partners, plus investors in the public company (NASDAQ: RXRX).
Availability: Enterprise partnerships and an internal drug pipeline — not a consumer or self-serve tool.
What people say
As a public company (NASDAQ: RXRX), Recursion's "reviews" are analyst notes and market reception, and they are decidedly mixed-to-cautious. It has genuine techbio credibility — one of the largest proprietary phenomics datasets, the BioHive-2 supercomputer (504 NVIDIA H100s) and a $50M NVIDIA investment — and major pharma partnerships that validate the platform. But Wall Street has been sceptical: coverage describes only limited buy ratings, a modest median price target around $8, and a stock that screens as expensive after a multi-year decline in shareholder returns.
The recurring criticisms are financial and clinical, not technological. Analysts point to sustained operating losses, heavy share dilution, high cash burn and substantial short interest, with meaningful revenue from internal drug candidates not expected until roughly 2027 or later. The deeper industry critique of AI-first drug discovery applies here too — impressive compute and data have not yet produced an approved, blockbuster drug, so the thesis remains largely unproven at the clinic.
Institutional positioning is split (roughly as many funds adding as trimming), which captures the mood: real assets and a differentiated platform, but a "show me the pipeline" stock where the AI story still has to convert into approved medicines.
Summary of public user & expert reviews, compiled by RECATOOLS.
About this listing
This entry was compiled from publicly available data including Recursion Pharmaceuticals's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Recursion Pharmaceuticals unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Recursion Pharmaceuticals directly →
Spotted something out of date? Suggest an update →
More in Research & Data
